Your Health, We Care
Anamorelin, as a new, oral, selective ghrelin receptor agonist, was launched in Japan in April 2021 for the treatment of cancer cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, colorectal cancer and other malignant tumors.
Clinical data shows that anamolin has the effect of increasing weight, muscle mass, and appetite in cancer cachexia patients.
Anamorelin is the first drug specifically for the treatment of cachexia launched···【more】
Release date：2024-08-20Recommended：145
Anamoreline is the world's first drug for the treatment of cancer cachexia, ···【more】
Release date：2024-08-19Recommended：159
Anamorelin, a drug that specializes in the treatment of cancer cachexia, was lau···【more】
Release date：2024-08-19Recommended：161
Through its distinctive mechanism of action, Anamorelin presents novel therapeut···【more】
Release date：2024-08-05Recommended：179
